Accelerated Development On The Cards In EU and US For Bluebird, Celgene’s CAR-T Therapy

Bluebird Bio and Celgene Corporation have succeeded in getting the chimeric antigen receptor T cell (CAR T-cell) therapy they are developing for use in previously treated multiple myeloma patients onto two key regulatory schemes that promise to accelerate the product’s development in the EU and the US.

bb2121 was this month accepted onto the European Medicines Agency’s priority medicines (PRIME) scheme for getting drugs for unmet medical needs to patients faster. The investigational product has also been...